Liping Zhang1, Hui Yu, Andrzej Badzio, Theresa A Boyle, Hans-Ulrich Schildhaus, Xian Lu, Rafal Dziadziuszko, Jacek Jassem, Marileila Varella-Garcia, Lynn E Heasley, Ashley A Kowalewski, Kim Ellison, Gang Chen, Caicun Zhou, Fred R Hirsch. 1. *Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, Shanghai, People's Republic of China; †Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; ‡Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; §Institute of Pathology, University Hospital Cologne, Medical Centre, Cologne, Germany; ‖Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado; ¶Department of Craniofacial Biology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; and #Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, Shanghai, People's Republic of China.
Abstract
INTRODUCTION: Small-cell lung cancer (SCLC) accounts for 15% of all lung cancers and has been understudied for novel therapies. Signaling through fibroblast growth factors (FGF2, FGF9) and their high-affinity receptor has recently emerged as a contributing factor in the pathogenesis and progression of non-small-cell lung cancer. In this study, we evaluated fibroblast growth factor receptor 1 (FGFR1) and ligand expression in primary SCLC samples. METHODS: FGFR1 protein expression, messenger RNA (mRNA) levels, and gene copy number were determined by immunohistochemistry (IHC), mRNA in situ hybridization, and silver in situ hybridization, respectively, in primary tumors from 90 patients with SCLC. Protein and mRNA expression of the FGF2 and FGF9 ligands were determined by IHC and mRNA in situ hybridization, respectively. In addition, a second cohort of 24 SCLC biopsy samples with known FGFR1 amplification by fluorescence in situ hybridization was assessed for FGFR1 protein expression by IHC. Spearman correlation analysis was performed to evaluate associations of FGFR1, FGF2 and FGF9 protein levels, respective mRNA levels, and FGFR1 gene copy number. RESULTS: FGFR1 protein expression by IHC demonstrated a significant correlation with FGFR1 mRNA levels (p < 0.0001) and FGFR1 gene copy number (p = 0.03). The prevalence of FGFR1 mRNA positivity was 19.7%. FGFR1 mRNA expression correlated with both FGF2 (p = 0.0001) and FGF9 (p = 0.002) mRNA levels, as well as with FGF2 (p = 0.01) and FGF9 (p = 0.001) protein levels. There was no significant association between FGFR1 and ligands with clinical characteristics or prognosis. In the second cohort of specimens with known FGFR1 amplification by fluorescence in situ hybridization, 23 of 24 had adequate tumor by IHC, and 73.9% (17 of 23) were positive for FGFR1 protein expression. CONCLUSIONS: A subset of SCLCs is characterized by potentially activated FGF/FGFR1 pathways, as evidenced by positive FGF2, FGF9, and FGFR1 protein and/or mRNA expression. FGFR1 protein expression is correlated with FGFR1 mRNA levels and FGFR1 gene copy number. Combined analysis of FGFR1 and ligand expression may allow selection of patients with SCLC to FGFR1 inhibitor therapy.
INTRODUCTION:Small-cell lung cancer (SCLC) accounts for 15% of all lung cancers and has been understudied for novel therapies. Signaling through fibroblast growth factors (FGF2, FGF9) and their high-affinity receptor has recently emerged as a contributing factor in the pathogenesis and progression of non-small-cell lung cancer. In this study, we evaluated fibroblast growth factor receptor 1 (FGFR1) and ligand expression in primary SCLC samples. METHODS:FGFR1 protein expression, messenger RNA (mRNA) levels, and gene copy number were determined by immunohistochemistry (IHC), mRNA in situ hybridization, and silver in situ hybridization, respectively, in primary tumors from 90 patients with SCLC. Protein and mRNA expression of the FGF2 and FGF9 ligands were determined by IHC and mRNA in situ hybridization, respectively. In addition, a second cohort of 24 SCLC biopsy samples with known FGFR1 amplification by fluorescence in situ hybridization was assessed for FGFR1 protein expression by IHC. Spearman correlation analysis was performed to evaluate associations of FGFR1, FGF2 and FGF9 protein levels, respective mRNA levels, and FGFR1 gene copy number. RESULTS:FGFR1 protein expression by IHC demonstrated a significant correlation with FGFR1 mRNA levels (p < 0.0001) and FGFR1 gene copy number (p = 0.03). The prevalence of FGFR1 mRNA positivity was 19.7%. FGFR1 mRNA expression correlated with both FGF2 (p = 0.0001) and FGF9 (p = 0.002) mRNA levels, as well as with FGF2 (p = 0.01) and FGF9 (p = 0.001) protein levels. There was no significant association between FGFR1 and ligands with clinical characteristics or prognosis. In the second cohort of specimens with known FGFR1 amplification by fluorescence in situ hybridization, 23 of 24 had adequate tumor by IHC, and 73.9% (17 of 23) were positive for FGFR1 protein expression. CONCLUSIONS: A subset of SCLCs is characterized by potentially activated FGF/FGFR1 pathways, as evidenced by positive FGF2, FGF9, and FGFR1 protein and/or mRNA expression. FGFR1 protein expression is correlated with FGFR1 mRNA levels and FGFR1 gene copy number. Combined analysis of FGFR1 and ligand expression may allow selection of patients with SCLC to FGFR1 inhibitor therapy.
Authors: Olivier E Pardo; Claudia Wellbrock; Umme K Khanzada; Muriel Aubert; Imanol Arozarena; Sally Davidson; Frances Bowen; Peter J Parker; V V Filonenko; Ivan T Gout; Neil Sebire; Richard Marais; Julian Downward; Michael J Seckl Journal: EMBO J Date: 2006-06-29 Impact factor: 11.598
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Carmen Behrens; Heather Y Lin; J Jack Lee; Maria Gabriela Raso; Waun Ki Hong; Ignacio I Wistuba; Reuben Lotan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Lindsay Marek; Kathryn E Ware; Alexa Fritzsche; Paula Hercule; Wallace R Helton; Jennifer E Smith; Lee A McDermott; Christopher D Coldren; Raphael A Nemenoff; Daniel T Merrick; Barbara A Helfrich; Paul A Bunn; Lynn E Heasley Journal: Mol Pharmacol Date: 2008-10-10 Impact factor: 4.436
Authors: Jingchuan Zhang; Lin Zhang; Xinying Su; Ming Li; Liang Xie; Florian Malchers; ShuQiong Fan; XiaoLu Yin; YanPing Xu; Kunji Liu; Zhengwei Dong; Guanshan Zhu; Ziliang Qian; Lili Tang; Jakob Schöttle; Ping Zhan; Qunsheng Ji; Elaine Kilgour; Paul D Smith; A Nigel Brooks; Roman K Thomas; Paul R Gavine Journal: Clin Cancer Res Date: 2012-10-18 Impact factor: 12.531
Authors: Hye Ryun Kim; Dae Joon Kim; Dae Ryong Kang; Jin Gu Lee; Sun Min Lim; Chang Young Lee; Sun Young Rha; Mi Kyung Bae; Young Joo Lee; Se Hoon Kim; Sang-Jun Ha; Ross Andrew Soo; Kyung Young Chung; Joo Hang Kim; Ji Hyun Lee; Hyo Sup Shim; Byoung Chul Cho Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Hui Yu; Cory Batenchuk; Andrzej Badzio; Theresa A Boyle; Piotr Czapiewski; Daniel C Chan; Xian Lu; Dexiang Gao; Kim Ellison; Ashley A Kowalewski; Christopher J Rivard; Rafal Dziadziuszko; Caicun Zhou; Maen Hussein; Donald Richards; Sharon Wilks; Marc Monte; William Edenfield; Jerome Goldschmidt; Ray Page; Brian Ulrich; David Waterhouse; Sandra Close; Jacek Jassem; Kimary Kulig; Fred R Hirsch Journal: J Thorac Oncol Date: 2016-09-14 Impact factor: 15.609
Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-02
Authors: Remco Nagel; Ana Teresa Avelar; Nanne Aben; Natalie Proost; Marieke van de Ven; Jan van der Vliet; Miranda Cozijnsen; Hilda de Vries; Lodewyk F A Wessels; Anton Berns Journal: Mol Cancer Ther Date: 2019-03-14 Impact factor: 6.261
Authors: Terry L Ng; Hui Yu; Derek E Smith; Theresa A Boyle; Emily R York; Scott Leedy; Dexiang Gao; Dara L Aisner; Adrie Van Bokhoven; Lynn E Heasley; Fred R Hirsch; D Ross Camidge Journal: Clin Lung Cancer Date: 2018-09-07 Impact factor: 4.785